Compare TECX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TECX | ENTA |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.0M | 374.6M |
| IPO Year | N/A | 2012 |
| Metric | TECX | ENTA |
|---|---|---|
| Price | $29.47 | $12.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $80.40 | $20.40 |
| AVG Volume (30 Days) | ★ 323.2K | 170.9K |
| Earning Date | 05-07-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $13.70 | $4.09 |
| 52 Week High | $35.99 | $17.15 |
| Indicator | TECX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 40.63 |
| Support Level | $16.83 | $12.09 |
| Resistance Level | $35.99 | $15.52 |
| Average True Range (ATR) | 2.85 | 0.81 |
| MACD | -0.27 | -0.17 |
| Stochastic Oscillator | 55.28 | 2.50 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.